French pharmaceutical giant Sanofi has entered into exclusive negotiations with US-based private equity firm Advent International to divest its European generics business Zentiva for €1.9bn.

Following the binding deal, the two companies plan to jointly work to establish a new independent operation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Zentiva offers a wide range of generic medicines across various therapeutic areas. The business caters to more than 40 million patients throughout 25 European countries.

Advent International European healthcare managing director and co-head Tom Allen, and French division managing director and head Cédric Chateau jointly commented: “We have long been attracted to the generics pharmaceutical sector as it enables more people to access high quality treatments by lowering their cost.

“Following a comprehensive review of strategic options for our generic unit in Europe, we have determined that transferring this business to Advent is the best option to ensure its long-term success.”

“We believe that Zentiva is a great platform, full of talented people, who we can invest behind to build a new, independent, European generics leader.”

Advent will support the management at Zentiva through investment in operations, production facilities, and the research and development pipeline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sanofi CEO Olivier Brandicourt said: “Zentiva is a robust business with a highly talented workforce and we believe it has demonstrated its potential for growth.

“Following a comprehensive review of strategic options for our generic unit in Europe, we have determined that transferring this business to Advent is the best option to ensure its long-term success.”

Subject to the finalisation of definitive agreements and regulatory approvals, the acquisition is expected to be completed by the end of this year.